Clinical Trials
7 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT03764553 2026-04-07
LyRICX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Active not recruiting
NCT05891171 2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting